Heparin-Induced Thrombocytopenia in Patients Undergoing Valvular and Aortic Surgery: A Modern Assessment of Risk

Abstract

Objective

The incidence and outcomes of patients with heparin-induced thrombocytopenia (HIT) are well defined for general cardiac surgical populations. The purpose of this study was to define the outcomes of patients with HIT in a population excluding patients who underwent coronary artery bypass grafting (CABG).

Methods

The local Society of Thoracic Surgeons cardiac surgical database was queried between January 2008 and May 2017 for patients who underwent either open valvular surgery or aortic surgery. Patients who underwent either isolated or combined CABG procedures were excluded. Cohorts were formed based on the presence or absence of postoperative HIT. Logistic regression models were built to determine the association between postoperative HIT and outcomes, adjusted for both preoperative and intraoperative variables.

Results

Of the total cohort (8,107 patients), 176 patients (2.2%) developed HIT after surgery. HIT patients experienced an increased incidence of morbidities postoperatively, including reoperation for bleeding, reoperation for cardiac and noncardiac etiologies, postoperative stroke, perioperative myocardial infarction, postoperative sternal infection, postoperative arrhythmia, new-onset renal failure, and dialysis (all with P < 0.01). The unadjusted 30-day mortality was 14.8% in HIT patients vs 4.9% in those without HIT (P < 0.01). After risk adjustment, reoperation for noncardiac events, renal failure, new dialysis, postoperative stroke, arrhythmia, and sternal wound infection remained significantly elevated in patients who developed postoperative HIT.

Conclusions

Patients who developed HIT after non-CABG cardiac surgery experienced increased postoperative rates of morbidity and mortality. Early diagnosis and treatment remained mainstays of therapy. Early identification of patients at highest risk should prompt careful risk stratification when possible.

Keywords

aortic surgery heparin thrombocytopenia valve surgery

Get full access to this article

View all access options for this article.

References

Arepally

GM.

Ortel

. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809–817.doi:10.1056/NEJMcp052967

Fathi

. Heparin-induced thrombocytopenia (HIT): identification and treatment pathways. Glob Cardiol Sci Pract 2018; 2018: 15.doi:10.21542/gcsp.2018.15

Girolami

Prandoni

Stefani

et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101: 2955–2959.doi:10.1182/blood-2002-07-2201

Eisman

Surrey

Ramachandran

et al. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 1990; 76: 336–344.doi:10.1182/blood.V76.2.336.336

Seigerman

Cavallaro

Itagaki

et al. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: an analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 2014; 28: 98–102.doi:10.1053/j.jvca.2013.07.021

Jones

HU.

Muhlestein

JB.

Jones

et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation 2002; 106(12 Suppl 1): I19–I22.

Mattioli

AV.

Bonetti

Zennaro

et al. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J 2009; 157: 589–595.doi:10.1016/j.ahj.2008.11.007

Welsby

IJ.

Milano

et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010; 110: 30–35.doi:10.1213/ANE.0b013e3181c3c1cd

Edwards

JT.

Hamby

JK.

Worrall

. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003; 75: 1622–1624.doi:10.1016/S0003-4975(02)04782-3

10.

Seider

Ross

Pretorius

et al. The use of cangrelor and heparin for anticoagulation in a patient requiring pulmonary thromboendarterectomy surgery with suspected heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 2019; 33: 1050–1053.doi:10.1053/j.jvca.2018.04.051

http://www.ncbi.nlm.nih.gov/pubmed/29853315

11.

Gernhofer

YK.

Ross

Khoche

et al. The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia. J Cardiothorac Surg 2018; 13: 30.doi:10.1186/s13019-018-0721-x